Opioid Antagonist Formulations
AssigneePurdue Pharma L.P.
InventorMargaret Moline
Life of this patent
Estimating the term…
Abstract
In certain embodiments, the present invention is directed to a solid controlled-release dosage form comprising a core comprising a core portion of an opioid antagonist and a shell encasing the core and comprising a shell portion of the opioid antagonist, wherein the release profile of the core portion of opioid antagonist is different than the release profile of the shell portion of opioid antagonist.
Claims22
A solid controlled-release dosage form comprising a core comprising a core portion of an opioid antagonist and a shell encasing the core and comprising a shell portion of the opioid antagonist, wherein a release profile of the core portion of opioid antagonist is different than the release profile of the shell opioid antagonist.
19-72. (canceled)
A method of preparing a solid controlled-release dosage form comprising preparing a core comprising a core portion of an opioid antagonist;
- and encasing the core with a shell comprising a shell portion of the opioid antagonist;
- wherein the release profile of the core portion of opioid antagonist is different than the release profile of the shell portion of opioid antagonist.
75-76. (canceled)
Dependencies are inferred from the claim text.